DISEASE AREA COMMERCIAL LEADER
GASTROENTEROLOGY AND IL-23 PATHWAY
Richard Appiah is Vice President, Disease Area Commercial Leader, Gastroenterology and IL-23 Pathway for the Immunology Therapeutic Area at Janssen Global Services. In this role, he is responsible for leading the commercial strategy to support the discovery, development, and launch of new therapeutics within the inflammatory bowel disease and IL-23 pathway areas.
Prior to this role, Richard served as Senior Director, Franchise Strategy Marketing for the U.S. Cardiovascular & Metabolism organization at Janssen, significantly contributing to growth of the XARELTO® (rivaroxaban) brand. Under his leadership, XARELTO established a first-of-its-kind, direct-to-patient commercial model designed to improve adherence and lower patients’ out-of-pocket cost. Richard joined Johnson & Johnson in 2002 and has held roles of increasing responsibility at Janssen in Oncology, Neuroscience, and Immunology.
Beyond his work at Johnson & Johnson, Richard spent four years at Pfizer in the specialty business unit where he was responsible for payer marketing and contracting strategies for a portfolio of biologic products.
Richard holds Bachelor and M.S. degrees from Syracuse University and an MBA from Harvard Business School.
Follow Richard on LinkedIn here.